Transcranial Magnetic Stimulation (TMS)

What it is

Transcranial magnetic stimulation occupies a unique niche: it is a focal, non-invasive brain stimulation delivered in an outpatient chair, without anesthesia, sedation, or cognitive side effects, yet it acts directly on cortical tissue rather than through the bloodstream. A rapidly changing magnetic field generated by a coil held against the scalp induces electrical currents in the underlying cortex, depolarizing neurons in a circumscribed region. Repeated over a course of daily sessions, this modulates the excitability of the targeted circuit and its downstream networks. TMS is the most widely used device-based treatment in psychiatry, the most actively iterated, and the clearest illustration of how biomarker-guided targeting is beginning to reshape an interventional modality.

How it works

The standard antidepressant target is the left dorsolateral prefrontal cortex (DLPFC), stimulated at high frequency (typically 10 Hz) to increase excitability; right DLPFC low-frequency (1 Hz) stimulation, which is inhibitory, is an alternative. The rationale is circuit-based rather than local: the DLPFC is a cortical node accessible from the scalp that is functionally connected to deeper limbic structures — most importantly the subgenual anterior cingulate (sgACC) — that cannot be reached directly. By modulating DLPFC excitability, TMS is thought to exert downstream, network-level effects on the dysregulated frontolimbic circuitry described in the DMN circuit account.

At the cellular level, repetitive stimulation induces long-term potentiation- and depression-like changes in synaptic strength — plasticity in the literal sense — connecting TMS to the neuroplasticity/BDNF convergence. The ability to measure this plasticity directly, via combined TMS-EEG, is one of the more promising target-engagement tools in the electrophysiology biomarker literature.

The evidence and the protocols

TMS efficacy is best understood through the evolution of its protocols, each addressing a limitation of the last.

Conventional rTMS. The pivotal trials (O'Reardon and colleagues, 2007; the sham-controlled OPT-TMS trial, George and colleagues, 2010) established efficacy for treatment-resistant depression and led to the first FDA clearance in 2008. Response and remission rates are moderate — meaningfully better than sham, but below ECT for severe illness. The honest framing is that TMS is a well-tolerated treatment of moderate efficacy, well suited to patients who have failed one or more medications but are not in the severity range that demands ECT.

Deep TMS. Using an H-coil to reach larger and somewhat deeper cortical volumes, deep TMS earned FDA clearance for depression (2013), obsessive-compulsive disorder (2018, targeting medial prefrontal and anterior cingulate cortex), smoking cessation (2020), and anxious depression — broadening the modality beyond mood disorders.

Theta-burst stimulation (TBS). Intermittent theta-burst stimulation (iTBS) compresses an excitatory protocol into roughly three minutes. The THREE-D trial (Blumberger and colleagues, 2018) demonstrated non-inferiority of iTBS to the standard 37-minute 10 Hz protocol, a logistical breakthrough that dramatically increased throughput without sacrificing efficacy.

Accelerated and targeted protocols. The most striking recent development is the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT/SNT) protocol (Cole and colleagues, 2020–2021), which combines three innovations: many sessions per day (ten) compressed into five days, individualized targeting using functional connectivity between the DLPFC and sgACC, and a high total dose. Small controlled trials reported remission rates far above conventional TMS, leading to FDA clearance in 2022. The results are genuinely exciting but rest on small samples and await larger replication — the appropriate posture is cautious optimism, not assumption.

Targeting: from a tape measure to connectomics

The history of TMS targeting recapitulates this library's argument about biomarker-guided care. Early practice located the DLPFC with the crude "5 cm rule" — a fixed distance from the motor cortex — which lands inconsistently across individual anatomy. The field has moved toward MRI-neuronavigation and, most importantly, functional-connectivity targeting: stimulating the DLPFC site most strongly anticorrelated with the sgACC predicts better outcomes (Fox, Cash, and colleagues). This is biomarker-guided neurostimulation in practice, and it is the mechanism by which SAINT individualizes its target — a concrete bridge between the neuroimaging biomarker program and clinical intervention.

Practical considerations

TMS's defining clinical advantage is tolerability. It requires no anesthesia, is performed in an outpatient setting, and — crucially — produces no cognitive impairment, the principal disadvantage of ECT. Side effects are largely limited to scalp discomfort and headache at the stimulation site, which attenuate over a course. The main serious risk is seizure, which is rare (on the order of well under 0.1% with adherence to safety guidelines) and which mandates screening for seizure threshold-lowering factors. A standard acute course historically ran daily sessions over four to six weeks; iTBS and accelerated protocols are collapsing this timeline substantially.

The convergence

TMS sits at the non-invasive, moderate-efficacy, high-tolerability position in the interventional spectrum, complementary to ECT rather than competitive with it. It operationalizes the neuroplasticity convergence through LTP/LTD-like synaptic change; it depends on the frontolimbic network architecture of the DMN account; and it is the modality most advanced in applying neuroimaging and electrophysiology biomarkers to individualize and verify treatment. It shares its sgACC target logic with deep brain stimulation, reaching the same structure non-invasively from the cortical surface.

Caveats — load-bearing, not decorative

Three caveats. First, efficacy is moderate: conventional TMS helps a meaningful fraction of medication-resistant patients but is not a match for ECT in severe illness, and framing it as equivalent overstates the evidence. Second, the accelerated-protocol results are preliminary: SAINT's remarkable remission rates come from small trials, and the field has been burned before by impressive early neurostimulation results that regressed on replication — these protocols are promising and FDA-cleared, but large-scale confirmation is pending. Third, targeting heterogeneity: outcomes depend on hitting the right individualized target, and the gap between connectivity-guided research protocols and routine scalp-landmark practice means real-world results may lag the published trials.

Bottom line

TMS is the workhorse of non-invasive neurostimulation: well-tolerated, free of cognitive side effects, FDA-cleared across an expanding set of indications, and of moderate efficacy in treatment-resistant depression. Its trajectory — from fixed-distance targeting toward connectivity-guided, accelerated, high-dose protocols like SAINT — is the clearest example in this series of biomarker-guided personalization improving an intervention, even as the most dramatic results await larger replication. It is best positioned for medication-resistant patients who do not require ECT-level intervention, and it is the modality to watch as imaging-based targeting matures.

Selected references

1. O'Reardon JP, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007.
2. George MS, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder (OPT-TMS): a sham-controlled randomized trial. Arch Gen Psychiatry. 2010.
3. Blumberger DM, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018.
4. Cole EJ, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for treatment-resistant depression (SAINT). Am J Psychiatry. 2020.
5. Cole EJ, et al. Stanford Neuromodulation Therapy (SNT): a double-blind randomized controlled trial. Am J Psychiatry. 2021.
6. Fox MD, et al. Efficacy of TMS targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biol Psychiatry. 2012.
7. Cash RFH, et al. Using brain imaging to improve spatial targeting of TMS for depression. Biol Psychiatry. 2021.
8. Lefaucheur JP, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update. Clin Neurophysiol. 2020.
9. Carpenter LL, et al. Transcranial magnetic stimulation for major depression: a multisite, naturalistic, observational study of acute treatment outcomes. Depress Anxiety. 2012.
10. Carmi L, et al. Efficacy and safety of deep TMS for obsessive-compulsive disorder: a prospective multicenter randomized double-blind placebo-controlled trial. Am J Psychiatry. 2019.
11. Brunoni AR, et al. Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: a systematic review with network meta-analysis. JAMA Psychiatry. 2017.
12. Mutz J, et al. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ. 2019.
13. Huang YZ, et al. Theta burst stimulation of the human motor cortex. Neuron. 2005.
14. McClintock SM, et al. Consensus recommendations for the clinical application of repetitive TMS in the treatment of depression. J Clin Psychiatry. 2018.
15. George MS, Post RM. Daily left prefrontal repetitive TMS for acute treatment of medication-resistant depression. Am J Psychiatry. 2011.
16. Williams NR, et al. High-dose spaced theta-burst TMS as a rapid-acting antidepressant. Brain. 2018.
17. Levkovitz Y, et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry. 2015.
18. Cole EJ, Phillips AL, et al. Accelerated TMS protocols: a review. Curr Behav Neurosci Rep. 2022.
19. Drysdale AT, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med. 2017.
20. Trapp NT, et al. Reliability of targeting methods in TMS for depression. Brain Stimul. 2020.